Takeda's Orzeyful gets Japan approval for narcolepsy type 1
Takeda Pharmaceutical's Orzeyful (oveporexton) is approved in Japan as the first and only medicine to treat the underlying cause of narcolepsy type 1, marking its third major regulatory approval worldwide.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.